<DOC>
	<DOCNO>NCT02080468</DOCNO>
	<brief_summary>The primary objective study assess effect ethinyl estradiol ( EE ) /norgestimate , weak cytochrome P450 ( CYP ) 3A4 inhibitor , pharmacokinetics ( PK ) lomitapide 2 primary metabolite , M1 M3 .</brief_summary>
	<brief_title>Evaluate Effect Ethinyl Estradiol/Norgestimate Pharmacokinetics Lomitapide Healthy Female Subjects</brief_title>
	<detailed_description>This study single center , randomize , open-label , 2 arm study evaluate effect EE/norgestimate , weak CYP3A4 inhibitor , PK lomitapide healthy female subject EE/norgestimate administer simultaneously lomitapide administration separate 12 hour .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>1 . Healthy female , 18 40 year age inclusive 2 . BMI 18.5 32.0 kg/m2 , inclusive ; total body weight &gt; 110 lb ( 50 kg ) ; 3. good health , determine clinically significant relevant abnormality identify detailed medical history 4. know history hypersensitivity previous intolerance lomitapide EE/norgestimate 5. creatine phosphokinase , AST , ALT level must 1.5 time upper limit normal 6. clinical laboratory evaluation within reference range test laboratory 7. negative test select drug abuse 8. negative hepatitis panel negative HIV antibody screen 9. childbearing potential ( ie , postmenopausal surgically sterile ) . All subject must negative serum beta pregnancy test . 10. able comprehend willing sign Informed Consent Form 1. significant history clinical manifestation metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , GI , neurological , psychiatric disorder 2. history unexplained breast abnormality abnormal uterine bleed 3. history significant hypersensitivity , intolerance , allergy drug compound , food , substance 4. history stomach intestinal surgery resection 5. history Gilbert 's Syndrome suspicion Gilbert 's Syndrome 6. subject abnormality 12lead ECG 7. use drug abuse 6 month prior Checkin ; 8. subject consume 14 unit alcohol per week significant history alcoholism drug/chemical abuse within 1 year prior Checkin 9. use tobacco nicotinecontaining product within 6 month prior Checkin ; 10. participation investigational study drug trial within 30 day prior Checkin ; 11. use prescription medications/products within 14 day prior Checkin unless deem acceptable Investigator Sponsor 12. use overthecounter , nonprescription preparation within 7 day prior Checkin , unless deem acceptable Investigator Sponsor 13. use alcohol , grapefruit ( include star fruit ) , caffeinecontaining food beverage within 72 hour prior Checkin Study Completion 14. use oral ( except schedule administration EE/norgestimate ) , implantable , injectable , transdermal contraceptive 15. use hormone replacement therapy 16. poor peripheral venous access ; 17. donation blood ( 500 mL ) 30 day prior Screening Study Completion 18. receipt blood product within 2 month prior Checkin ; 19. acute chronic condition , schedule hospitalization ( inclusive elective surgery study ) schedule travel prior completion study procedure , opinion Investigator , would limit subject 's ability complete and/or participate clinical study ; 20. subject , opinion Investigator , participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Effect</keyword>
	<keyword>Ethinyl Estradiol/Norgestimate</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Lomitapide .</keyword>
</DOC>